Hang Quach

University of Melbourne

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (10)

Zoe McQuilten

AUSTRALIA

View details

David Siegel

Chief, Myeloma Division

UNITED STATES

View details

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES

View details

Craig Thomas Wallington-Gates

Flinders University

AUSTRALIA

View details

S. Zweegman

NETHERLANDS

View details

Holger Auner

Full Professor (Professeur ordinaire)

University of Lausanne

SWITZERLAND

View details

Reuben Benjamin

Consultant Haematologist and Clinical Senior Lecturer

King's College Hospital

UNITED KINGDOM

View details

hareth nahi

Karolinska University Hospital

SWEDEN

View details

Gareth Gregory

MONASH UNIVERSITY

AUSTRALIA

View details

Elizabeth Moore

MONASH UNIVERSITY

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hang Quach

Research Interests

Explore related searches

Contact this professor

Articles (11)

The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.

Collaborators (10)

Zoe McQuilten

David Siegel

Ola Landgren

Craig Thomas Wallington-Gates

S. Zweegman

Holger Auner

Reuben Benjamin

hareth nahi

Gareth Gregory

Elizabeth Moore

Make your next move.